loading
Cogent Biosciences Inc stock is traded at $9.08, with a volume of 1.83M. It is up +0.22% in the last 24 hours and down -23.70% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
See More
Previous Close:
$9.06
Open:
$9.05
24h Volume:
1.83M
Relative Volume:
1.69
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-227.05M
P/E Ratio:
-4.1273
EPS:
-2.2
Net Cash Flow:
$-177.93M
1W Performance:
-12.69%
1M Performance:
-23.70%
6M Performance:
+15.82%
1Y Performance:
+20.58%
1-Day Range:
Value
$8.93
$9.30
1-Week Range:
Value
$8.56
$10.49
52-Week Range:
Value
$3.67
$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name
Name
Cogent Biosciences Inc
Name
Phone
617-945-5576
Name
Address
275 WYMAN STREET, WALTHAM
Name
Employee
164
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
COGT's Discussions on Twitter

Compare COGT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
COGT 9.08 1.00B 0 -227.05M -177.93M -2.20
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-26-24 Downgrade Robert W. Baird Outperform → Neutral
Feb-08-24 Initiated Citigroup Buy
Dec-11-23 Downgrade Wedbush Outperform → Neutral
Dec-08-23 Initiated JP Morgan Overweight
Apr-28-23 Initiated Robert W. Baird Outperform
Mar-27-23 Resumed H.C. Wainwright Buy
Dec-14-22 Initiated Needham Buy
Jun-28-22 Initiated Guggenheim Buy
Oct-11-21 Initiated H.C. Wainwright Buy
Jun-09-21 Resumed Jefferies Buy
Dec-23-20 Initiated Piper Sandler Overweight
Oct-14-20 Initiated Ladenburg Thalmann Buy
View All

Cogent Biosciences Inc Stock (COGT) Latest News

pulisher
Nov 18, 2024

Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Trend Tracker for (COGT) - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 16, 2024

Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartz

Nov 13, 2024
pulisher
Nov 13, 2024

Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Cogent Biosciences Reports Strong Pipeline Progress, $346M Cash Position Despite Q3 Losses | COGT Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Creative Planning Buys 3,272 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Nov 12, 2024
pulisher
Nov 08, 2024

Cogent Biosciences’ (COGT) Buy Rating Reaffirmed at HC Wainwright - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

FMR LLC Acquires Additional Shares in Cogent Biosciences Inc - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

(COGT) Trading Advice - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 05, 2024

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3%Here's What Happened - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Cogent Biosciences Announces Bezuclastinib Presentations at - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Cogent Biosciences to Present Key Bezuclastinib Trial Data at ASH 2024 Meeting | COGT Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Cogent Biosciences' (COGT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.67 Average PT from Brokerages - Defense World

Nov 03, 2024
pulisher
Oct 31, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

(COGT) Investment Analysis - Stock Traders Daily

Oct 26, 2024
pulisher
Oct 26, 2024

Hennion & Walsh Asset Management Inc. Purchases 44,287 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Oct 26, 2024
pulisher
Oct 24, 2024

Cogent Biosciences' (COGT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

Cogent Biosciences expands pipeline with KRAS inhibitor - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Cogent Biosciences expands pipeline with KRAS inhibitor By Investing.com - Investing.com UK

Oct 23, 2024
pulisher
Oct 23, 2024

Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics - StockTitan

Oct 23, 2024
pulisher
Oct 23, 2024

Cogent Biosciences Announces Pipeline Expansion into KRAS - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

COGT Stock Hits 52-Week High at $12.2 Amid Market Optimism - Investing.com India

Oct 23, 2024
pulisher
Oct 22, 2024

Cogent Biosciences (NASDAQ:COGT) Sets New 52-Week HighHere's What Happened - MarketBeat

Oct 22, 2024
pulisher
Oct 20, 2024

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Yahoo Finance

Oct 20, 2024
pulisher
Oct 19, 2024

SG Americas Securities LLC Acquires New Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

The Manufacturers Life Insurance Company Has $301,000 Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Market Momentum Report: Cogent Biosciences Inc (COGT)’s Negative Close at 11.35 - The Dwinnex

Oct 17, 2024
pulisher
Oct 16, 2024

Cogent Biosciences (NASDAQ:COGT) Shares Down 2.4%What's Next? - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

(COGT) Technical Data - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 14, 2024

Stocks of Cogent Biosciences Inc (COGT) are poised to climb above their peers - SETE News

Oct 14, 2024
pulisher
Oct 10, 2024

Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.6%Here's What Happened - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Did Cogent Biosciences Inc (COGT) perform well in the last session? - US Post News

Oct 09, 2024
pulisher
Oct 09, 2024

Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target - Insider Monkey

Oct 09, 2024
pulisher
Oct 08, 2024

Get in on Cogent Biosciences Inc’s (COGT) buy-in window today! - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Metric Deep Dive: Understanding Cogent Biosciences Inc (COGT) Through its Ratios - The Dwinnex

Oct 08, 2024
pulisher
Oct 08, 2024

Dimensional Fund Advisors LP Has $7.84 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Oct 08, 2024

Cogent Biosciences Inc Stock (COGT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):